CJC-1295 is one of the most searched peptides in Australia. Here is what it is, what the research has examined, what legal access looks like, and how to get a proper prescription.
Start free assessment →This page is for general information purposes only. CJC-1295 is a prescription-only medicine in Australia. Access requires assessment and prescription from an AHPRA-registered medical practitioner. Always consult a qualified doctor before making any decisions about your health.
CJC-1295 is one of the most searched peptides in Australia. It is a synthetic analogue of growth hormone releasing hormone that has been extensively researched for its interaction with growth hormone signalling pathways and the downstream effects on body composition, recovery, and metabolic function. This page covers what it is, what the research has examined, and what proper access looks like in Australia.
CJC-1295 is a synthetic analogue of growth hormone releasing hormone, the naturally occurring hormone produced by the hypothalamus that signals the pituitary gland to release growth hormone. Natural GHRH is rapidly degraded in the bloodstream. CJC-1295 was developed with chemical modifications that extend its half-life, allowing it to interact more persistently with GHRH receptors and produce a more sustained stimulation of growth hormone release.
The version most commonly prescribed is CJC-1295 with DAC, where DAC refers to a drug affinity complex modification that extends the half-life to approximately one to two weeks. This allows for less frequent administration compared to shorter-acting growth hormone releasing peptides.
Research into CJC-1295 has examined its effects on growth hormone and IGF-1 levels, body composition markers including lean mass and fat mass, recovery from training, sleep quality, and various metabolic parameters. Growth hormone plays a central role in tissue repair, body composition regulation, and metabolic function, and declines progressively from the mid-twenties. CJC-1295 is studied for its potential to support growth hormone output in the context of this age-related decline.
CJC-1295 is frequently prescribed in combination with Ipamorelin because the two compounds work through different receptor pathways that both influence growth hormone release. CJC-1295 acts on the GHRH receptor while Ipamorelin acts on the ghrelin receptor, and combining them may produce a more robust growth hormone stimulation than either compound alone.
CJC-1295 requires blood monitoring: Because CJC-1295 influences IGF-1 production as a downstream effect of growth hormone stimulation, blood monitoring of IGF-1 and related markers is standard practice at UHD BioHealth. Updated blood test results are required before continuation protocols are approved. This is a clinical safeguard that ensures the prescribing doctor has objective data to inform ongoing decisions about the protocol.
Yes, when accessed through the proper framework. CJC-1295 is a Schedule 4 prescription-only medicine in Australia. It is legal to access when prescribed by an AHPRA-registered medical practitioner following a clinical assessment and dispensed through a licensed Australian compounding pharmacy. It cannot legally be purchased without a prescription or sourced from overseas or unregulated domestic channels.
CJC-1295 is on the WADA prohibited list for competitive sport as a growth hormone releasing hormone analogue. Competitive athletes subject to anti-doping regulations cannot use it regardless of whether it is accessed through a legitimate prescription.
Complete your health history and goals online. Takes around five minutes and costs nothing.
An AHPRA-registered prescribing doctor reviews your information and prepares a personalised protocol if appropriate.
Once you choose to proceed, your prescription goes to a licensed Australian compounding pharmacy. Cold-chain delivery to your door.
Free assessment, AHPRA-registered prescribing doctor, licensed Australian compounding pharmacy. No cost until you choose to proceed.